KalVista Pharmaceuticals (KALV) Earns Daily Media Sentiment Score of 0.06

News coverage about KalVista Pharmaceuticals (NASDAQ:KALV) has been trending somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. KalVista Pharmaceuticals earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 46.2578685587237 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of brokerages have issued reports on KALV. ValuEngine upgraded KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st. BTIG Research increased their price target on KalVista Pharmaceuticals from $18.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, October 16th.

KalVista Pharmaceuticals (NASDAQ:KALV) opened at $10.01 on Friday. KalVista Pharmaceuticals has a 1 year low of $5.48 and a 1 year high of $15.80.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, December 14th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.05). The business had revenue of $1.13 million for the quarter. KalVista Pharmaceuticals had a negative return on equity of 70.20% and a negative net margin of 1,379.58%.

COPYRIGHT VIOLATION WARNING: “KalVista Pharmaceuticals (KALV) Earns Daily Media Sentiment Score of 0.06” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/14/kalvista-pharmaceuticals-kalv-given-daily-news-sentiment-score-of-0-06.html.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

Insider Buying and Selling by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply